The firm also said this week that it plans to submit data to the FDA from an adjuvant trial of giredestrant in ER-positive, HER2-negative breast cancer.

The firms submitted data from the Phase III DESTINY-Breast05 trial comparing Enhertu to Roche's antibody-drug conjugate Kadcyla.

After a data monitoring committee saw increased risk of secondary blood cancers in the SYPHONY-1 trial, the firm will stop selling the drug for follicular lymphoma and sarcoma.

The House of Lords science and technology committee seeks answers to questions regarding the implementation of treatments like CAR T-cell and gene therapies.

The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.

The company plans to combine the CAR designs with its in-house delivery platform to advance its in vivo CAR-M therapies toward clinical studies.

Two former FDA veterans are worried that a "firewall" between politics and scientific regulatory decisions has been breached, risking the agency's reputation and leadership.

Day One received accelerated approval in the US in 2024 for Ojemda to treat pediatric low-grade glioma with a BRAF fusion or rearrangement or BRAF V600 mutation.

The collaboration initially will focus on developing an mRNA therapy for a type of lung fibrosis and an ASO for Lamb-Shaffer syndrome.

The trial will include patients with MTAP-deleted pancreatic or MTAP-deleted RAS-mutant non-small cell lung cancer.

The group has already helped pass bills in Arkansas and Oklahoma, and is supporting bills introduced in Florida, Mississippi, and Tennessee.

The deal could be worth more than $1 billion, if all genetic targets identified lead to approved therapeutics.